Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants

Medical Care - United States
doi 10.1097/mlr.0b013e31815cecc3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Cancer in Older Adults: Understanding Cause and Effects of Chemotherapy-Related Toxicities

Future Oncology
MedicineCancer ResearchOncology
2019English

A Method to Predict Breast Cancer Stage Using Medicare Claims

Epidemiologic Perspectives & Innovations
2010English

Measuring Underuse of Necessary Care Among Elderly Medicare Beneficiaries Using Inpatient and Outpatient Claims

JAMA - Journal of the American Medical Association
Medicine
2000English

External Validation of Medicare Claims for Breast Cancer Chemotherapy Compared With Medical Chart Reviews

Medical Care
EnvironmentalPublic HealthOccupational Health
2006English

A Concise History of the Cancer and Leukemia Group B

Clinical Cancer Research
Cancer ResearchOncology
2006English

Cancer and Leukemia Group B Cancer Control and Health Outcomes Committee: Origins and Accomplishments

Clinical Cancer Research
Cancer ResearchOncology
2006English

Non-Infectious Chemotherapy-Associated Acute Toxicities During Childhood Acute Lymphoblastic Leukemia Therapy

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2017English

Mortality Differences Between Traditional Medicare and Medicare Advantage: A Risk-Adjusted Assessment Using Claims Data

Inquiry
Health Policy
2017English

Improved Efficacy Using Rituximab and Brief Duration, High Intensity Chemotherapy With Filgrastim Support for Burkitt or Aggressive Lymphomas: Cancer and Leukemia Group B Study 10 002

British Journal of Haematology
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy